TJX initiated with an Outperform at Daiwa
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
25 minutes ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Business Insider
an hour ago
- Business Insider
IBM's Data Breach Report Warns that AI Tools Are Growing Hacker Targets
Tech giant IBM (IBM) recently released its 2025 Cost of a Data Breach Report, which showed that companies are adopting artificial intelligence far faster than they are securing it. For the first time, the report looked at breaches that involved AI systems and found that 13% of organizations experienced an AI-related breach, while another 8% did not even know if they had been compromised. Among those affected, 97% lacked basic security controls for AI systems, which resulted in 60% of incidents exposing data and 31% disrupting operations. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One major issue identified in the report is 'shadow AI,' or unauthorized AI tools that are being used within organizations. These tools were linked to one in five breaches and typically cost $670,000 more to fix than breaches that did not involve shadow AI. They also exposed more sensitive data, such as personal information and intellectual property, compared to the global average. Furthermore, attackers themselves are now using AI in their methods, with 16% of breaches involving tactics like AI-driven phishing and deepfake impersonation. Despite these rising threats, 63% of breached companies have no formal AI governance policies, and even among those that do, only 34% regularly audit for unsanctioned AI use. As a result, the financial impact of breaches is significant. Globally, the average cost of a breach dropped slightly to $4.44 million, but U.S. breaches reached a record $10.22 million. Healthcare breaches continue to be the most expensive, averaging $7.42 million, and take the longest to contain. Interestingly, though, organizations that use AI and automation in their security operations saved an average of $1.9 million in breach costs and shortened the time to resolve breaches by 80 days, which shows that AI can be a powerful defense when properly managed. Is IBM a Buy, Sell, or Hold? Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on seven Buys, four Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $297.33 per share implies 18.9% upside potential.
Business Insider
an hour ago
- Business Insider
Tesla Stock (TSLA) Faces New Trauma as European Sales Keep Sliding
Shares in EV maker Tesla (TSLA) reversed today as it suffered another European sales slowdown. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to new official industry data, sales of the company's vehicles declined in France and Denmark for the seventh consecutive month. Nordic Nightmare Tesla, led by chief executive Elon Musk, registered 1,307 new cars in France last month, representing a 27% drop compared to July 2024. In Denmark, the decline was even steeper, with sales falling 52% to 336 vehicles. Model Y registrations specifically decreased by 49% in Denmark during July. Tesla's struggles extended to Sweden as well, where new car registrations plummeted 85.8% year-on-year to just 163 vehicles in July, based on data released today by Mobility Sweden. The figures were down 83.3% from June's total of 976 vehicles. In July, the Elon Musk-led company registered 117 Model Y units, 44 Model 3s, and one unit each of the Model S and Model X. This is despite Tesla currently offering a 40,000 SEK trade-in bonus for customers purchasing a Model Y or Model 3 from July 18 to August 15, and taking delivery by August 30. As can be seen below, the U.S. and China dominate Tesla sales, but Europe remains an important market. Tesla Ecosystem The news today builds on figures last week from the European Automobile Manufacturers' Association (ACEA), which revealed that Tesla sold 70,655 vehicles in the European Union in the first half of 2025. That was down 43.7% year over year. It continues a challenging year for Tesla whose sales worldwide have been hit by increased competition from rivals such as China's BYD (BYDDY), concerns over its design appeal, threats to EV subsidies in the U.S. and a hit to its brand reputation by Musk's on and very much off involvement with President Trump's administration. Not everyone is a Tesla doubter, however, with some analysts pointing to the overall strength of the Tesla ecosystem as a reason for optimism in the stock. Indeed, some see it as heading towards a staggering $10 trillion market value based on its innovations in human-like robots, self-driving and energy storage. Is TSLA a Good Stock to Buy Now? On TipRanks, TSLA has a Hold consensus based on 14 Buy, 15 Hold and 8 Sell ratings. Its highest price target is $500. TSLA stock's consensus price target is $310.84, implying a 0.83% upside.
